Solifenacin/tamsulosin - Astellas Pharma

Drug Profile

Solifenacin/tamsulosin - Astellas Pharma

Alternative Names: EC905; Solifenacin succinate/tamsulosin hydrochloride; Tamsulosin hydrochloride/solifenacin succinate; Tamsulosin/solifenacin; Urizia; Vesomni; Volutsa

Latest Information Update: 23 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Rovi
  • Class Antispasmodics; Quinuclidines; Small molecules; Sulfonamides; Urologics
  • Mechanism of Action Alpha 1a adrenergic-receptor antagonists; Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Benign prostatic hyperplasia

Most Recent Events

  • 30 Apr 2015 No recent reports on development identified - Phase-III for Benign prostatic hyperplasia in Austria, Belarus, Belgium, France, Germany, Hungary, Italy, Poland, Russia and Slovakia (PO)
  • 11 Feb 2015 Rovi acquires the marketing rights of solifenacin/tamsulosin in Spain
  • 01 Sep 2013 Launched for Benign prostatic hyperplasia in Netherlands (PO) - first global launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top